These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 11995445

  • 1. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
    Ridolfi L, Ridolfi R.
    Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ.
    J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
    [Abstract] [Full Text] [Related]

  • 7. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ.
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ, Malya R, Rawat A.
    Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.
    J Immunother; 2006 Jun; 29(5):545-57. PubMed ID: 16971810
    [Abstract] [Full Text] [Related]

  • 15. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F, Piacentini MG, Franciosi C, Caprotti R, De Fina S, Cesana G, Uggeri F, Conti M, Uggeri F.
    Hepatogastroenterology; 2004 Jun; 51(60):1872-6. PubMed ID: 15532847
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
    Hofbauer GF, Baur T, Bonnet MC, Tartour E, Burg G, Berinstein NL, Dummer R.
    Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
    Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, Gonzalez R.
    Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
    [Abstract] [Full Text] [Related]

  • 19. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
    Lissoni P, Mengo S, Bucovec R, Brivio F, Fumagalli L, Tancini G, Gardani GS.
    In Vivo; 2003 Aug; 17(1):73-5. PubMed ID: 12655794
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.